Humanigen, PCI Pharma Services Enter Lenzilumab Partnership

Humanigen, Inc., a biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ entered into an agreement with PCI Pharma Services (PCI), a global contract development manufacturing organization (CDMO), to provide importation, release and commercialization services in the UK for lenzilumab. Under the agreement, PCI will purchase lenzilumab for resale and distribution in the event a Conditional Marketing Authorization is received in the UK for use in patients hospitalized with COVID-19.
 
“We continue our commercial preparation in the UK and in parallel are working closely with the Medicines and Healthcare products Regulatory Agency (MHRA) to address regulatory requirements for a potential Conditional Marketing Authorization. With its global reach, PCI will provide a critical function in the supply chain, by directly purchasing lenzilumab for further distribution in the UK and facilitating this key process for Humanigen,” said Edward Jordan, Chief Commercial Officer. “It is anticipated that we will complete our response to MHRA soon after the top-line results from the ACTIV-5/BET-B clinical trial with lenzilumab are received.”
 
If authorized, lenzilumab will offer an important treatment option to patients hospitalized with COVID-19. Hospitalizations from COVID-19 continue in the UK with more than 235,000 admitted year-to-date and with ~5,000 currently hospitalized. Humanigen believes that treatment with lenzilumab may deliver economic value to the healthcare system. Previously published research has demonstrated that treatment with lenzilumab may save the National Health Service over £10,000 per patient.